Neurophth Therapeutics
Neurophth is China's first gene therapy company for ophthalmic diseases.
Neurophth Therapeutics operates in biotechnology, life science based in Asia-Pacific (APAC), founded in 2016.
Neurophth Therapeutics is positioned in biotechnology, life science, a segment that rewards a clear, focused offering.
Asia-Pacific (APAC) is where the company is located.
Its current recorded stage is Series_C.
Its team size is recorded as c_00251_00500 employees.
Total disclosed funding stands at about $237.4M.
| Sector | Biotechnology, Life Science |
|---|---|
| Headquarters | Asia-Pacific (APAC) |
| Founded | 2016 |
| Employees | c_00251_00500 |
| Stage | series_c |
| Total funding | $237,394,768 |
Website: www.neurophth.com
Sign in to view the contact information we hold for Neurophth Therapeutics.
Create a free account
Create a free account